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CASE REPORT Open Access
The genetic basis of hyaline fibromatosis
syndrome in patients from a
consanguineous background: a case series
Leila Youssefian1,4†, Hassan Vahidnezhad1,2†, Andrew Touati1,3†, Vahid Ziaee5†, Amir Hossein Saeidian1,
Sara Pajouhanfar1, Sirous Zeinali2,6 and Jouni Uitto1*
Abstract
Background: Hyaline fibromatosis syndrome (HFS) is a rare heritable multi-systemic disorder with significant
dermatologic manifestations. It is caused by mutations in ANTXR2, which encodes a transmembrane receptor
involved in collagen VI regulation in the extracellular matrix. Over 40 mutations in the ANTXR2 gene have been
associated with cases of HFS. Variable severity of the disorder in different patients has been proposed to be related
to the specific mutations in these patients and their location within the gene.
Case presentation: In this report, we describe four cases of HFS from consanguineous backgrounds. Genetic
analysis identified a novel homozygous frameshift deletion c.969del (p.Ile323Metfs*14) in one case, the
previously reported mutation c.134 T > C (p.Leu45Pro) in another case, and the recurrent homozygous
frameshift mutation c.1073dup (p.Ala359Cysfs*13) in two cases. The epidemiology of this latter mutation is of
particular interest, as it is a candidate for inhibition of nonsense-mediated mRNA decay. Haplotype analysis
was performed to determine the origin of this mutation in this consanguineous cohort, which suggested that
it may develop sporadically in different populations.
Conclusions: This information provides insights on genotype-phenotype correlations, identifies a previously
unreported mutation in ANTXR2, and improves the understanding of a recurrent mutation in HFS.
Keywords: Hyaline fibromatosis syndrome, Genodermatoses, Mutation analysis, HFS, ANTXR2 gene
Background
Hyaline fibromatosis syndrome (HFS, OMIM# 228600)
is a rare heritable disorder with variable severity and
frequent lethality, characterized by thickened skin with
nodules, papules and plaques, often with a periorificial
and perianal distribution, gingival hypertrophy, and joint
contractures. Osteopenia, predisposition to respiratory
infections, and diarrhea are often present.
HFS is an autosomal recessive disorder, caused by mu-
tations in the ANTXR2 gene, also referred to as CMG2.
This gene encodes ANTXR2, a type I transmembrane
protein initially characterized for its role in angiogenesis
and as a receptor for the anthrax toxin [1, 2]. While over
40 mutations in the ANTXR2 gene have been reported
in association with HFS so far, most of them (~70%) be-
ing missense and frameshift mutations scattered along
the protein, the molecular pathogenesis of this disease
has only recently begun to be understood. Specifically,
ANTXR2 has been shown to act as a receptor for colla-
gen VI, promoting lysosome-mediated degradation of
collagen VI in the extracellular matrix [3], consistent
with the finding that patients with HFS develop an accu-
mulation of collagen VI [4]. Thus, defective collagen VI
degradation due to nonfunctional ANTXR2 likely leads
to collagen accumulation in patients’ tissues, resulting in
the clinical manifestations of HFS.
In this report, we examine four patients from consan-
guineous Iranian backgrounds diagnosed with HFS, and
present their clinical and genetic findings (Table 1).
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Case presentation
Case 1 presented in infancy with dusky, erythematous
plaques and hyperpigmentation over the torso and joints
(Fig. 1a). Painful joint contractures, recurrent diarrhea,
gingival hypertrophy, and recalcitrant upper respiratory
tract infections were present. The patient died from
infectious complications at 6 months of age.
Case 2 presented at 1 month of age with joint contrac-
tures, skin thickening, hyperpigmentation, and perianal
plaques (Fig. 1b). The patient died at 10 months of
age following recurrent respiratory infections and
severe diarrhea.
Case 3 presented neonatally with painful contractures
of the lower extremities (Fig. 1c). The patient developed
papular lesions on the forehead, nose and ears, as well
as hyperpigmentation over the medial malleoli. Gingival
hyperplasia was present, and the patient developed
frequent respiratory infections.
Case 4 presented in infancy with painful contractures
of the legs and interphalangeal joints, perianal erythema-
tous plaques, and perioral papules (Fig. 1d). Additional
features included hyperpigmentation over the medial
malleoli, gingival hypertrophy, recurrent diarrhea, and
respiratory infections. The patient died at 18 months of
age from infectious complications. On the basis of clin-
ical presentations, HFS was suspected in all four cases.
Genetic analysis of DNA isolated from peripheral
blood of each proband was performed using PCR-based
amplification using 17 pairs of primers spanning all
exons and ~ 50 bp of flanking intronic sequences of the
ANTXR2 gene (NM_058172; primer sequences available
upon request). PCR products were bidirectionally se-
quenced using an automated sequencer (3730; Applied
Biosystems, Foster City, CA, USA). Sequencing revealed
a previously unreported homozygous frameshift deletion
mutation c.969del (p.Ile323Metfs*14) in exon 12 in Case
1, and the previously reported homozygous missense
mutation c.134 T > C (p.Leu45Pro) in exon 1 in Case 2
[5]. A homozygous frameshift insertion c.1073dup (p.
Ala359Cysfs*13) in exon 13 was identified in Cases 3
and 4. This mutation has been identified in several
previous cases of HFS, including an Iranian case re-
ported by our laboratory [6]. The mutation occurs in a
cytosine/guanosine rich region of DNA that has been
suggested to be prone to mutational events including in-
sertions and deletions [7, 8].
To determine whether this c.1073dup (p.Ala359-
Cysfs*13) mutation was due to independent mutational
events at this hotspot, or due to a single distant founder
effect mutation in the Iranian population, haplotype ana-
lysis was performed using a series of informative single
nucleotide polymorphisms (SNPs) around the ANTXR2
gene (Table 2). HapMap data (https://snpinfo.niehs.nih.
gov/snpinfo/snptag.html) were used to choose tag SNPs,
spanning a region of 2.91 Mb encompassing the ANXTR2
gene. Selected tag SNPs were rs4692955, rs1493177,
rs12509909, rs10011562, rs7685006, rs4975133, rs4975132,
and rs4975131 (https://www.ncbi.nlm.nih.gov/SNP). Five
intragenic SNPs in ANTXR2 were additionally included as
tag SNPs: rs13140055, rs4594664, rs11730210, rs4336166,
and rs12647691 (https://www.ncbi.nlm.nih.gov/SNP). Over-
all, 13 SNPs were genotyped by PCR (primer sequences
available upon request) and bidirectionally sequenced using
an automated sequencer (3730; Applied Biosystems).
Haplotype analysis was performed in Cases 3 and 4, as
well as in our previously reported Iranian case of HFS
with the same c.1073dup (p.Ala359Cysfs*13) mutation
[6] (Table 2). Comparison of the haplotypes of these
Table 1 Clinical and genetic findings in four patients with HFS
Case 1 Case 2 Case 3 Case 4
Mutation in the
ANTXR2 gene
c.969del
(p.Ile323Metfs*14)
c.134 T > C
(p.Leu45Pro)
c.1073dup
(p.Ala359Cysfs*13)
c.1073dup
(p.Ala359Cysfs*13)
Parental
consanguinity
First cousin First cousin First cousin,
once removed
First cousin
Status Deceased
(6 months)
Deceased
(10 months)
Alive
(2 years old)
Deceased
(1.5 years)
Age of onset 3 months 1 month Birth Birth
Skin findings Erythematous plaques on
torso, hyperpigmentation,
skin thickening
Perianal plaques,
hyperpigmentation,
skin thickening
Papular lesions on forehead, ears,
and around the nose, hyperpigmentation, skin
thickening
Perianal plaques, perioral
papules, hyperpigmentation,
skin thickening
Joint contractures/
pain
+ + + +
Low bone density + – – –
Gingival hypertrophy + + + +
Recurrent diarrhea + + – +
Respiratory infections + + + +
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three Iranian patients showed a lack of haplotype
conservation for SNPs in this region.
Discussion and conclusions
Collectively, these cases add to the genetic understand-
ing of HFS. Cases with mutations in the exons encoding
the cytoplasmic tail of ANTXR2 protein have been
reported to be clinically less severe than those with mu-
tations upstream in the gene, which is likely to be due to
the role of the cytoplasmic tail in receptor turnover, ra-
ther than directly in ligand-binding [9]. While Cases 3
and 4 harbored truncating mutations affecting the cyto-
plasmic tail, the upstream frameshift mutation in Case 1
is predicted to result in a truncated protein, likely
impairing receptor stability in the cellular membrane.
Case 2 harbored a mutation in the von Willebrand
domain, essential for ligand binding, including to colla-
gen VI [3]. Case 1 and 2 had the most severe phenotypes
Fig. 1 Clinical and genetic findings in four cases of HFS. Pedigrees displaying consanguinity, clinical findings, and Sanger sequencing of the
identified ANTXR2 mutations. In each case, the upper sequence panel represents the mutant allele, as compared to reference sequence in a
healthy control below. a Clinical features of Case 1 included erythematous plaques, hyperpigmentation, and joint contractures of the lower
extremities. Sanger sequencing identified a novel homozygous mutation, c.969del, which is predicted to result in truncated protein product,
p.Ile323Metfs*14. b First cousin consanguinity, lower extremity contractures with hyperpigmentation over the medial malleolus, and Sanger
sequencing of the c.134C > T (p.Leu45Pro) mutation in Case 2. c Case 3 developed flesh-colored papules on the face, including periauricular
lesions, as well as gingival hyperplasia. Sequencing revealed the recurrent mutation c.1073dup (p.Ala359Cysfs*13). d Case 4 presented with
characteristic perianal lesions and perioral papules. The same mutation as in Case 3 was identified by Sanger sequencing. The green in Case 3
and 4 represents the amino acid change, p.Ala357Pro, resulting from a common benign polymorphism, c.1069G > C (rs12647691)
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and earliest lethality, supporting the notion that muta-
tions upstream of the cytoplasmic tail domain result in
increased phenotypic severity.
The consequences of specific frameshift mutations in
the ANTXR2 gene have previously been examined,
including the c.1073dup (p.Ala359Cysfs*13) mutation
disclosed in Cases 3 and 4 [10]. Patients who are homo-
zygous for this mutation have ANTXR2 mRNA expres-
sion levels that are half of those found in normal
individuals [11]. However, the protein product of this
mutated form of ANTXR2 has been shown to reach the
cell membrane with partial functionality [10]. Thus, this
mutation is a candidate for targeted inhibition of
nonsense-mediated mRNA decay. The c.1073dup (p.
Ala359Cysfs*13) mutation has been reported multiple
times previously, and understanding the inheritance and
epidemiology of this mutation in different populations is
important in determining which HFS patients would
benefit from potential therapy. While this mutation
could be expected to have developed in isolated muta-
tional events in most cases, we sought to determine the
inheritance pattern of this mutation in a highly consan-
guineous population of Iran, in which inheritance of re-
current mutations causing recessive diseases is often due
to transmission of a mutated haplotype from a com-
mon ancestor through generations, i.e., the founder
effect. The haplotype analysis of our three patients
showed that the haplotypes harboring this mutation
are identical by state, but not by descent, which sup-
ports the notion that this mutation is not the result
of a founder effect in this Iranian cohort. Conse-
quently, this mutation may occur sporadically in different
populations, and therapeutic approaches targeting this
mutation would likely have benefits in any population af-
fected by HFS.
This study reports a novel causative mutation in HFS,
contributes to our understanding of genotype-phenotype
correlations for this syndrome, and improves our under-
standing of a recurrent ANTXR2 gene mutation that
may be a candidate for targeted therapy.
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